Quantbot Technologies LP Fate Therapeutics Inc Transaction History

Quantbot Technologies LP

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$2.02 - $5.04 $77,164 - $192,528	38,200 Added 410.75%	47,500 $100,000
Q2 2023 Aug 08, 2023	BUY	$4.76 - $6.59 $43,316 - $59,969	9,100 Added 4550.0%	9,300 $44,000
Q1 2023 May 12, 2023	SELL	$4.24 - $11.12 $114,056 - $299,128	-26,900 Reduced 99.26%	200 $1,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $23.83 $236,640 - $571,920	24,000 Added 774.19%	27,100 $273,000
Q3 2022 Nov 07, 2022	BUY	$21.04 - $36.06 $65,224 - $111,786	3,100 New	3,100 $69,000
Q4 2021 Feb 11, 2022	SELL	$47.84 - $64.34 $517,533 - $696,030	-10,818 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$59.27 - $95.73 $621,268 - $1 Million	10,482 Added 3119.64%	10,818 $641,000
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $9,684 - $13,322	144 Added 75.0%	336 $29,000
Q1 2021 May 14, 2021	BUY	$72.16 - $117.4 $1,515 - $2,465	21 Added 12.28%	192 $15,000
Q4 2020 Feb 12, 2021	SELL	$38.09 - $100.95 $27,196 - $72,078	-714 Reduced 80.68%	171 $15,000
Q3 2020 Nov 16, 2020	BUY	$30.41 - $40.5 $26,912 - $35,842	885 New	885 $35,000
Q1 2020 May 13, 2020	SELL	$17.28 - $31.88 $63,936 - $117,956	-3,700 Closed	0 $0
Q4 2019 Feb 10, 2020	BUY	$13.39 - $20.73 $45,526 - $70,482	3,400 Added 1133.33%	3,700 $72,000
Q3 2019 Nov 12, 2019	BUY	$15.47 - $22.5 $4,641 - $6,750	300 New	300 $4,000
Q3 2018 Nov 13, 2018	SELL	$8.75 - $16.29 $647 - $1,205	-74 Closed	0 $0
Q2 2018 Aug 13, 2018	SELL	$9.16 - $13.48 $99,935 - $147,066	-10,910 Reduced 99.33%	74 $0
Q1 2018 May 11, 2018	BUY	$6.3 - $13.77 $69,199 - $151,249	10,984 New	10,984 $107,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $235M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Quantbot Technologies LP, based on Form 13F filings with the SEC.

Stay updated on Quantbot Technologies LP with notifications on news.